PDCD1 and head and neck squamous cell carcinoma: In addition to the existing FDA-approved PD-1 inhibitors, nivolumab and pembrolizumab, emerging agents targeting PD-1 and CTLA4 are under ongoing clinical trials for HNSCC patients (3).